You can buy or sell FibroGen and other stocks, options, ETFs, and crypto commission-free!
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Read More The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 22
FibroGen's Roxadustat Shows A Clear Positive Phase III MACE Result, But Future Sales Remain Uncertain
FibroGen's (NASDAQ:FGEN) stock price has experienced a rocky ride in the past month. During the after hour on May.9th, it dropped more than 20% after the announcement of its Roxadustat's seven Phase III result with pooled MACE (Major Adverse Cardiovascular Events) analysis for US and MACE+ (MACE with plus hospitalization due to heart failure or unstable angina) for EU. However, the market seems to be confused by this outcome. Before jumping into the result, let's first understand how important MACE/MACE+ o...
Yahoo FinanceMay 9
FibroGen Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Expected Aug 7, After Hours